CERU Profile
Cerulean
Pharma Inc. (CERU) was a clinical stage company that focused on the
development of nanoparticle-drug conjugates (NDCs) to treat cancer.
The company's proprietary technology platform utilized nanotechnology
to create small, spherical particles that were designed to deliver
therapeutic payloads to tumors. The NDCs were engineered to be taken
up selectively by cancer cells and to release their therapeutic
payloads in a controlled manner, thereby reducing toxicity to healthy
tissue.
Cerulean's lead product candidate, CRLX101, was a NDC
that delivered the chemotherapeutic agent camptothecin. The company
conducted clinical trials of CRLX101 in a variety of cancer
indications, including ovarian cancer, renal cell carcinoma, and
non-small cell lung cancer. In July 2017, Cerulean announced that it
had discontinued development of CRLX101 and was exploring strategic
alternatives, including the potential sale of the company.
In
addition to CRLX101, Cerulean had a pipeline of other NDC candidates
in preclinical development. These included CRLX301, which was designed
to deliver the chemotherapeutic agent docetaxel, and CRLX121, which
was designed to deliver the B-cell lymphoma-2 (BCL-2) inhibitor
venetoclax.
Cerulean was founded in 2005 and was headquartered
in Waltham, Massachusetts. The company was publicly traded on the
NASDAQ exchange under the ticker s
|
